Hims & Hers Health (NYSE:HIMS) Given Hold Rating at Needham & Company LLC

Hims & Hers Health (NYSE:HIMS - Get Free Report)'s stock had its "hold" rating reiterated by stock analysts at Needham & Company LLC in a research note issued on Monday, MarketBeat.com reports.

Several other equities research analysts have also recently issued reports on the stock. Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday, June 15th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and an average target price of $38.31.

Hims & Hers Health Stock Up 12.0%

NYSE:HIMS traded up $4.96 during trading hours on Monday, hitting $46.37. 64,151,410 shares of the stock traded hands, compared to its average volume of 22,859,260. The company has a market cap of $10.38 billion, a price-to-earnings ratio of 67.20, a price-to-earnings-growth ratio of 1.56 and a beta of 2.09. Hims & Hers Health has a 1 year low of $13.47 and a 1 year high of $72.98. The stock has a 50 day moving average price of $49.27 and a 200 day moving average price of $39.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business's quarterly revenue was up 110.7% on a year-over-year basis. During the same period last year, the firm earned $0.05 earnings per share. Equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Melissa Baird sold 33,333 shares of Hims & Hers Health stock in a transaction on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $20,755,039.74. This trade represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Irene Becklund sold 2,203 shares of the company's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. The trade was a 21.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 706,454 shares of company stock valued at $35,220,112 over the last three months. 13.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Smartleaf Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after buying an additional 227 shares during the period. Allworth Financial LP raised its stake in shares of Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. SlateStone Wealth LLC raised its stake in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after buying an additional 413 shares during the last quarter. Finally, Kilter Group LLC boosted its stake in Hims & Hers Health by 1.0% in the 1st quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after purchasing an additional 450 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.